Topas Therapeutics GmbH
Topas Therapeutics is a biotech company advancing liver-directed tolerance therapies for autoimmune and immune-mediated diseases, with a lead candidate TPM502 in Phase 2a trials for celiac disease.
Classification
Profile
Funding
Funding details not yet available.
Establishes liver-directed immune tolerance for autoimmune diseases using a differentiated platform technology, demonstrated by positive Phase 2a results in celiac disease.
Patients with autoimmune and immune-mediated diseases, specifically targeting conditions like celiac disease through clinical development.
empty string
empty string
European Union Innovative Medicines Initiative (IMI) via the ToleranceInduction consortium
Research and development costs associated with advancing lead candidate TPM502 and conducting clinical trials.
Innovative platform technology for liver-directed tolerance, lead candidate TPM502, and specialized team expertise.
Advancing immune tolerance therapies, conducting clinical studies, and developing targeted treatments for immune-driven diseases.
empty string
Competes in the autoimmune therapy space by offering a unique liver-directed tolerance approach, distinguishing itself through specific platform technology.
Lack of targeted therapies for autoimmune and immune-mediated diseases; need for effective immune tolerance induction.
- Pipeline diversification: Accelerate IND filings for at least two additional high-prevalence autoimmune diseases (e.g., type-1 diabetes,
Short-term: Leverage Phase 2a success to secure a licensing partner for TPM502, unlocking milestone cash for Phase 2b · Mid-term: Use the TPC platform as a “plug-and-play” engine to rapidly add antigens, creating a portfolio of disease-modifying therapies that · Long-term: Position Topas as the go-to “immune-tolerance platform” in the biotech ecosy
- Clinical validation: Phase 2a data in celiac disease demonstrated both safety and functional immune tolerance, a rare milestone for a bio
No investors recorded yet.